Cargando…
Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma
Autores principales: | Enssle, Julius C., Campe, Julia, Büchel, Sarah, Moter, Alina, See, Frederic, Grießbaum, Katharina, Rieger, Michael A., Wolf, Sebastian, Ballo, Olivier, Steffen, Björn, Serve, Hubert, Rabenau, Holger F., Widera, Marek, Bremm, Melanie, Huenecke, Sabine, Ciesek, Sandra, von Metzler, Ivana, Ullrich, Evelyn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116569/ https://www.ncbi.nlm.nih.gov/pubmed/35588736 http://dx.doi.org/10.1016/j.ccell.2022.05.003 |
Ejemplares similares
-
Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma
por: Enßle, Julius C., et al.
Publicado: (2022) -
Portraying Immunity to Sars-Cov-2 after mRNA-Vaccination in Patients with Multiple Myeloma
por: Enssle, Julius Christoph, et al.
Publicado: (2022) -
PB2070: IMMUNE RESPONSES AFTER SARS-COV-2 MRNA-VACCINATION AND INFECTION AT SINGLE CELL RESOLUTION IN PATIENTS WITH MULTIPLE MYELOMA
por: Enssle, Julius C., et al.
Publicado: (2023) -
COVID-19 in multiple-myeloma patients: cellular and humoral immunity against SARS-CoV-2 in a short- and long-term view
por: von Metzler, Ivana, et al.
Publicado: (2021) -
Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study
por: Kohmer, Niko, et al.
Publicado: (2023)